 |
Drug Insight: Choosing a Drug Treatment Strategy for Women With Osteoporosis--An Evidence-Based Clinical Perspective CME DisclosuresRelease Date: April 8, 2008; Valid for credit through April 8, 2009 |
| Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | |
| Contents of This CME Activity | |
| To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.
- Drug Insight: Choosing a Drug Treatment Strategy for Women With Osteoporosis--An Evidence-Based Clinical Perspective
Piet P. Geusens, MD, PhD
Christian H. Roux, MD
David M. Reid, MB, ChB, MD
Willem F. Lems, MD
Silvano Adami, MD
Jonathan D. Adachi, MD, FRCPC
Philip N. Sambrook, MD, FRACP, LLB
Kenneth G. Saag, MD
Nancy E. Lane, MD
Marc C. Hochberg, MD, MPH
Go to Test Questions |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Identify differences in action between different classes of fracture prevention drugs
- List the most likely factors determining fracture risk profile in women
- Describe risk reduction for vertebral, nonvertebral, and hip
fractures for different fracture prevention drugs
- Describe risk reduction in all-cause mortality associated with the use of fracture prevention drugs
- Identify adverse effects of fracture prevention drugs
Authors and Disclosures Piet P. Geusens, MD, PhD
Disclosure: Piet P. Geusens, MD, PhD, has
disclosed that he has received grant or research support from and is on the speakers' bureau for Eli Lily, Merck, Procter and Gamble Pharmaceuticals, Roche and Servier. Christian H. Roux, MD
Disclosure: Christian H. Roux, MD, has disclosed that he is on the speakers' bureau for Actelion, the Alliance for Better Bone Health (Procter and Gamble Pharmaceuticals and Sanofi-Aventis), GlaxoSmithKline, Eli Lily,
Merck, Novartis Pharmaceuticals, Nycomed, Roche and Servier. David M. Reid, MB, ChB, MD
Disclosure: David M. Reid, MB, ChB, MD, has disclosed that he has received grant or research support from and is on the speakers' bureau for Novartis and Roche, and has acted as a consultant for Roche, Procter and Gamble Pharmaceuticals, and Amgen. Willem F. Lems, MD
Disclosure: Willem F. Lems, MD, has disclosed that he is on the speakers' bureau for Alliance for Better Bone Health (Procter and Gamble Pharmaceuticals and Sanofi-Aventis), Eli Lily, Merck, Roche and Servier. Silvano Adami, MD
Disclosure: Silvano Adami, MD, has disclosed no relevant financial relationships. Jonathan D. Adachi, MD, FRCPC
Disclosure: Jonathan D. Adachi, MD, FRCPC, has disclosed that he is on the speakers' bureau for Amgen, Eli Lily, GlaxoSmithKline, Merck, Novartis Pharmaceuticals, Pfizer, Procter and Gamble Pharmaceuticals, Roche, Sanofi-Aventis and Servier. Philip N. Sambrook, MD, FRACP, LLB
Disclosure: Philip N. Sambrook, MD, FRACP, LLB, has disclosed no relevant financial relationships.
Kenneth G. Saag, MD, MSc
Disclosure: Kenneth G. Saag, MD, MSc, has disclosed that he is on the speakers' bureau for Merck and Amgen, has received grant or research support from Amgen, Eli Lily, Novartis, Roche, Procter and Gamble Pharmaceuticals and Sanofi-Aventis, and has acted as a consultant for Amgen, Eli Lily, Merck, Novartis, Roche, Procter and Gamble Pharmaceuticals and Sanofi-Aventis. Nancy
E. Lane, MD
Disclosure: Nancy E. Lane, MD, has disclosed no relevant financial relationships. Marc C. Hochberg, MD, MPH
Disclosure: Marc C. Hochberg, MD, MPH, has disclosed that he has acted as a consultant for Amgen, Merck, Novartis Pharmaceuticals, Procter and Gamble Pharmaceuticals and Roche. Désirée Lie, MD, MSEd
Disclosure:
Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships. Rachel Ashton
Disclosure: Rachel Ashton has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
